Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 17
Updated:4/6/2019
Start Date:August 28, 2013
End Date:April 29, 2019
Contact:Novartis Pharmaceuticals
Email:novartis.email@novartis.com
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

The purpose of this study is to estimate the maximum tolerated dose and/or recommended dose
for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor
activity and characterize single and multiple-dose pharmacokinetics when administered orally
to pediatric patients with ALK-activated tumors, with and without food.

LDK378 is a novel inhibitor of ALK that is active in a broad range of ALK-activated tumor
models, including models driven by mutated versions of ALK known to be resistant to
crizotinib, and by ALK gene amplification.

The primary purpose of this study is to determine the maximum tolerated dose and/or
recommended dose for expansion in pediatric patients, and to delineate a clinical dose to be
used in any future pediatric studies, with and without food. This study will also assess the
safety, tolerability, PK and preliminary evidence of antitumor activity of LDK378 in
pediatric patients with neuroblastoma, and other ALK-activated tumors.

Inclusion Criteria:

- Diagnosed with a locally advanced or metastatic malignancy that has progressed despite
standard therapy, or for which no effective standard therapy exists

- Age ≥ 12 months and < 18 years

- The tumor must carry a genetic alteration of ALK

- Patients must have evaluable or measurable disease

Exclusion criteria:

- Symptomatic central nervous system (CNS) metastases who are neurologically unstable or
require increasing doses of steroids or local CNS-directed therapy (such as
radiotherapy, surgery or intrathecal chemotherapy) to control their CNS disease

- Clinically significant, uncontrolled heart disease

- Inadequate end organ function as defined by specified laboratory values

- Use of medications that are known to be strong inhibitors or inducers of CYP3A4/5 that
cannot be discontinued at least 1 week prior to start of treatment with LDK378 and for
the duration of the study

- Use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be
discontinued at least 1 week prior to start of treatment with LDK378 and for the
duration of the study.

- History of interstitial lung disease or interstitial pneumonitis, including clinically
significant radiation pneumonitis

- History of pancreatitis or history of increased amylase or lipase that was due to
pancreatic disease.

- Medications with a known risk of prolongation of QT interval

Other protocol defined inclusion and exclusion criteria may apply
We found this trial at
7
sites
885 2nd Avenue
New York, New York 10017
Principal Investigator: Shakeel Modak
Phone: 646-888-5716
?
mi
from
New York, NY
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Thomas Cash
Phone: 404-785-3535
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Boston, Massachusetts 02115
Principal Investigator: Suzanne Shusterman
Phone: 617-582-7169
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Eric Schafer
Phone: 832-824-4570
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Randwick, New South Wales 2031
?
mi
from
Randwick,
Click here to add this to my saved trials